Plasma Cell Dyscrasias

Diagnostic Evaluation

A comprehensive diagnostic workup including bone marrow examination, imaging, and additional laboratory testing should be performed to confirm the diagnosis of Waldenström's macroglobulinemia in patients with elevated kappa free light chain and IgM levels, as recommended by the International Workshop on Waldenström's Macroglobulinemia 1 and the International Myeloma Working Group 2, 3
The diagnostic workup should include a comprehensive metabolic panel (calcium, creatinine, albumin), serum protein electrophoresis, immunofixation, quantitative immunoglobulins, and serum free light chain assay, as recommended by the International Workshop on Waldenström's Macroglobulinemia 1 and the International Myeloma Working Group 2, 3

A complete diagnostic panel for suspected plasma cell dyscrasias should include:

Test	Description
Serum protein electrophoresis (SPEP)	Measures serum protein levels
Immunofixation (SIFE)	Identifies specific immunoglobulins
Quantitative immunoglobulins (IgG, IgA, IgM)	Measures immunoglobulin levels
Serum free light chain assay (kappa and lambda levels with ratio)	Measures free light chain levels
Complete blood count with differential	Measures blood cell counts
Comprehensive metabolic panel including calcium, creatinine, albumin	Measures metabolic parameters

Bone marrow aspiration and biopsy with immunophenotyping, and CT scan of chest, abdomen, and pelvis are recommended for IgM MGUS/WM diagnosis, as recommended by the International Workshop on Waldenström's Macroglobulinemia 1
The National Comprehensive Cancer Network recommends bone marrow biopsy to evaluate the percentage of plasma cells, with the presence of clonal plasma cells (>10% suggestive of myeloma) 4
Diagnostic evaluation should include assessment for defining events of myeloma, such as hypercalcemia, renal insufficiency, anemia, and bone lesions 4

Treatment initiation depends on the presence of hyperviscosity symptoms, significant cytopenias, bulky disease/organomegaly, symptomatic peripheral neuropathy, or other WM-related complications, according to the International Workshop on Waldenström's Macroglobulinemia 1
For patients with hyperviscosity or need for rapid tumor reduction, proteasome inhibitor-based therapy (e.g. Bortezomib/dexamethasone/rituximab), or Bendamustine/rituximab, or Ibrutinib may be considered, as recommended by the International Workshop on Waldenström's Macroglobulinemia 1
For patients with cytopenias without urgent need for response, Dexamethasone/rituximab/cyclophosphamide, Bendamustine/rituximab, or Ibrutinib may be considered, as recommended by the International Workshop on Waldenström's Macroglobulinemia 1
Bortezomib/dexamethasone-based regimens are recommended for patients with renal impairment, and cyclophosphamide, thalidomide, or daratumumab may be added based on disease characteristics, as suggested by the American Society of Hematology 2 and the National Comprehensive Cancer Network 5

Regular monitoring without immediate treatment, with follow-up every 3-6 months initially, then annually if stable, is recommended for patients with IgM MGUS, as suggested by the Haematologica guidelines 3
Serial measurement of IgM levels, serum free light chain levels and ratio, and evaluation of clinical symptoms related to disease should be performed regularly, as recommended by the International Workshop on Waldenström's Macroglobulinemia 1
Repeat bone marrow examination to assess response as clinically indicated, and consider plasmapheresis for patients with symptomatic hyperviscosity or very high IgM levels at risk for hyperviscosity syndrome, as recommended by the International Workshop on Waldenström's Macroglobulinemia 1
Amyloidosis screening with fat pad, bone marrow, or rectal biopsy with Congo red staining should be considered if clinical suspicion of amyloidosis exists, according to the Haematologica guidelines 3
Evaluating renal function is crucial, as renal impairment can cause elevation of both kappa and lambda light chains while maintaining a normal ratio, and in severe renal impairment, the "normal" free light chain ratio range may be wider (0.34-3.10), as recommended by the National Comprehensive Cancer Network 6

Response assessment should follow International Myeloma Working Group criteria, which includes serial measurement of serum free light chains to track disease activity, and stringent complete response (sCR) is defined as negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow, and normal free light chain ratio, as defined by the International Myeloma Working Group 7, 8, 9
Therapeutic plasma exchange (TPE) is considered for patients with very high FLC levels and renal impairment due to cast nephropathy, aiming for at least 50-60% reduction in serum FLC concentration, as suggested by the European Society for Medical Oncology 2, the Blood Cancer Journal 6, 10, and the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 6, 10
Consider which serum free light chain assay is being used (FreeLite vs. N Latex) as they have different performance characteristics in renal impairment, as noted by the American Society of Nephrology 11
Use the same assay (FreeLite or N Latex) for serial measurements to ensure accurate monitoring of patients with suspected plasma cell disorder, as advised by the European Renal Association 11
Evaluate patients with elevated free light chains by reviewing renal function and checking for signs of end-organ damage, such as hypercalcemia, anemia, bone lesions, and unexplained proteinuria, as recommended by the American Society of Clinical Oncology and other organizations 11